Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, OH.
Department of Anesthesiology and Pain Medicine, The Ohio State University, Columbus, OH.
J Cardiothorac Vasc Anesth. 2021 Aug;35(8):2338-2344. doi: 10.1053/j.jvca.2020.11.061. Epub 2020 Dec 2.
To characterize the impact, on failure to rescue, of cerebrovascular accident as a first postoperative complication after thoracic endovascular aortic aneurysm repair (TEVAR).
A retrospective cohort study using of National Surgical Quality Improvement Program Participants User File.
United States hospitals taking part in the National Surgical Quality Improvement Program.
Patients >18 years, who underwent TEVAR for nonruptured thoracic aortic aneurysm between 2005 and 2018, and developed one or more major postoperative complications within 30 days after surgery.
None.
Out of 3,937 patients who underwent TEVAR for nonruptured thoracic aneurysm, 1,256 (31.9%) developed major postoperative complications (stroke incidence: 11.4% [143/1256]). In adults <65 years old, the occurrence of stroke as the primary complication, relative to the occurrence of other complications, was associated with ten times greater risk of failure to rescue (29.4% v 4.6%; odds ratio [OR]: 10.10; 95% confidence interval [CI] 2.45-41.56; p < 0.001). The effect size was relatively lower when stroke occurred but was not the primary complication (20.0% v 4.6%; OR: 7.55; 95% CI 1.37-41.71; p = 0.020). In patients ≥65 years, the occurrence of stroke as the primary complication did not carry the similar prognostic value.
Younger patients who developed stroke were up to ten times more likely to die, relative to patients who developed other major complications. Survival was substantially reduced when stroke was the primary complication. The authors' findings imply that to maximize the survival of patients undergoing TEVAR, efforts may be needed to predict and prevent stroke occurrence as a primary postoperative morbidity event.
描述胸主动脉腔内修复术(TEVAR)后,脑血管意外作为术后第一个并发症对未能抢救成功的影响。
使用国家外科质量改进计划参与者用户文件的回顾性队列研究。
参与国家外科质量改进计划的美国医院。
2005 年至 2018 年间接受 TEVAR 治疗非破裂性胸主动脉瘤且术后 30 天内发生 1 种或多种主要术后并发症的>18 岁患者。
无。
在 3937 例接受非破裂性胸主动脉瘤 TEVAR 的患者中,1256 例(31.9%)发生主要术后并发症(卒中发生率:11.4%[143/1256])。在<65 岁的成年人中,与发生其他并发症相比,作为主要并发症发生卒中与未能抢救成功的风险增加十倍相关(29.4%比 4.6%;比值比[OR]:10.10;95%置信区间[CI]:2.45-41.56;p<0.001)。当卒中发生但不是主要并发症时,效果大小相对较低(20.0%比 4.6%;OR:7.55;95%CI:1.37-41.71;p=0.020)。在≥65 岁的患者中,卒中作为主要并发症的发生并没有类似的预后价值。
发生卒中的年轻患者死亡的可能性是发生其他主要并发症患者的十倍。当卒中作为主要并发症时,生存率显著降低。作者的研究结果表明,为了最大限度地提高接受 TEVAR 治疗的患者的生存率,可能需要努力预测和预防卒中作为主要术后发病率事件的发生。